These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Acute graft-versus-host disease in thalassaemic marrow transplantation with low-dose antithymocyte globulin. Khojasteh HN; Zakerinia M; Ramzi M; Haghshenas M East Mediterr Health J; 1999 May; 5(3):465-9. PubMed ID: 10793825 [TBL] [Abstract][Full Text] [Related]
27. Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Johnston L Best Pract Res Clin Haematol; 2008 Jun; 21(2):177-92. PubMed ID: 18503985 [TBL] [Abstract][Full Text] [Related]
28. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
30. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin. Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944 [TBL] [Abstract][Full Text] [Related]
35. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM). Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A; Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047 [TBL] [Abstract][Full Text] [Related]
36. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296 [TBL] [Abstract][Full Text] [Related]
37. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation. Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511 [TBL] [Abstract][Full Text] [Related]
38. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation. Mattsson J; Uzunel M; Remberger M; Hassan M Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093 [TBL] [Abstract][Full Text] [Related]
39. Fludarabine, cyclophosphamide, anti-thymocyteglobulin, and low-dose total body irradiation conditioning enables 1-HLA-locus-mismatched hematopoietic stem cell transplantation for very severe aplastic anemia without affecting ovarian function. Okuda S; Terasako K; Oshima K; Sato M; Nakasone H; Kako S; Yamazaki R; Tanaka Y; Tanihara A; Higuchi T; Nishida J; Kanda Y Am J Hematol; 2009 Mar; 84(3):167-9. PubMed ID: 19195036 [TBL] [Abstract][Full Text] [Related]
40. Anti-T-lymphocyte globulin based non-myeloablative stem cell transplantation followed by HLA-identical donor lymphocyte infusion for hematologic malignancies. Mao P; Wang S; Wang H; Li Q; Xu Y; Mo W; Ying Y; Zhu Z Chin Med J (Engl); 2003 Jan; 116(1):70-3. PubMed ID: 12667392 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]